<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">
 <italic>Ad5-nCoV</italic> from CanSino Biologicals Inc. is a recombinant vaccine using Adenovirus-vector. CanSino has an adenovirus-vector vaccine for Ebola (Ad5-EBOV) that is in phase II trials. Phase I trial has been completed on 108 volunteers; however, results have not been disclosed as of today. At present phase II trials are underway, and CanSino plans to enroll 500 volunteers to evaluate vaccine safety and immunogenicity.
 <xref rid="bib73" ref-type="bibr">
  <sup>73</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib74" ref-type="bibr">
  <sup>74</sup>
 </xref>
</p>
